Maria Juliana Majado

Publications (2)3.87 Total impact

• Article: Splenic rupture in a plasma cell leukemia, mobilized with G-CSF for autologous stem cell transplant.

  Consuelo Funes, Faustino Garcia-Candel, Maria Juliana Majado, Consuelo González-García, Agueda Bas, Eduardo Salido, Jose M Moraleda, Alfonso Morales
  [show abstract] [hide abstract]
  ABSTRACT: Splenic rupture (SR) is a rare adverse event observed in patients treated with G-CSF as a peripheral hematopoietic stem cell (PHSC) mobilizing agent, mostly in myeloma multiple and amiloidosis; to date, to our knowledge, it has not been previously described in plasma-cell leukemia (PCL). We report a case of a woman with PCL, who presented a SR after PHSC mobilization with Cyclophosphamide+G-CSF. The spleen removed showed hematopoietic foci and amiloid material. In the course of a second mobilization, 2 months after, the patient died from sepsis. We considered it important to report this case, in order to keep in mind the possibility of SR in patients with malignant gammopathy.
  Journal of Clinical Apheresis 01/2010; 25(4):223-5. · 1.93 Impact Factor
• Article: Large-volume-apheresis facilitates autologous transplantation of hematopoietic progenitors in poor mobilizer patients.

  Maria Juliana Majado, Alfredo Minguela, Consuelo González-García, Eduardo Salido, Miguel Blanquer, Consuelo Funes, Carmen Luisa Insausti, Ana María García-Hernández, José María Moraleda, Alfonso Morales
  [show abstract] [hide abstract]
  ABSTRACT: Given that pre-apheresis CD34(+) cell count (PA-CD34) predicts the apheresis' yield, a minimum of 5 to 20 PA-CD34/microl is required in many institutions to initiate cell collection. The aim of this study was to clarify whether large-volume-apheresis (LVA) could facilitate progenitor cell transplantation in patients with low PA-CD34. Apheresis was initiated in 226 patients, disregarding PA-CD34, at days: +5 in G-CSF, +10 in cyclophosphamide+G-CSF, and +15 to +20 in other chemotherapy+G-CSF mobilization, when leucocytes >2.5 x 10(9)/L. Four times the blood volume was processed. Patients were grouped according to their PA-CD34: >or=10/microl (group-A, n = 143); <10/microl but >or=5/microl (group-B, n = 40) and <5/microl (group-C, n = 43). No differences were found in diagnoses, gender, age, previous treatments or mobilization regimen between groups. Enough CD34(+) cells (>1.9 x 10(6)/kg) were obtained in 31 patients (72%) from group-C, although in this group two mobilizations were needed in 20 patients (46.5%), compared to 5 (3.5%) and 1 (2.5%) in groups A and B, respectively (P < 0.01). Evenly three apheresis or more were required in 28 patients (65.1%) from group-C, compared to 8 (5.6%) and 6 (15.0%) in groups A and B, respectively (P < 0.01). In conclusion LVA can facilitate autologous transplantation in poor-mobilizer-patients, low PA-CD34 should not be an inflexible exclusion factor.
  Journal of Clinical Apheresis 01/2009; 24(1):12-7. · 1.93 Impact Factor